Peter Johnson
Impact in
- Pathology and Forensic Medicine top 0.02%
- Lymphoma Diagnosis and Treatment
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 223
- Immunology 172
- Reproductive System and Pregnancy 64
- Immune Cell Function and Interaction 39
- Co-authors
- Martin J. Glennie (30 shared papers)Judith Nicola Bulmer (14 shared papers)John A. Radford (48 shared papers)W. Pagé Faulk (11 shared papers)Graham Packham (28 shared papers)Mark Steven Cragg (25 shared papers)Ruth R. French (13 shared papers)ANDREW S. JACK (19 shared papers)
- Journals
- Blood (65 papers)Hematological Oncology (34 papers)Journal of Clinical Oncology (29 papers)Journal of Reproductive Immunology (27 papers)British Journal of Haematology (24 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Peter Johnson
654 papers receiving 30.5k citations
Peter Johnson's Hit Papers
Peers
Comparison fields: 5 of 202
- Pathology and Forensic Medicine 12.0k
- Genetics 5.7k
- Immunology 7.5k
- Oncology 8.7k
- Obstetrics and Gynecology 1.6k
Countries citing papers authored by Peter Johnson
This map shows the geographic impact of Peter Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Johnson more than expected).
Fields of papers citing papers by Peter Johnson
This network shows the impact of papers produced by Peter Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Johnson. The network helps show where Peter Johnson may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 685 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Hit paper breakdown → | 2013 | 1373 |
| 2 | Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Hit paper breakdown → | 1998 | 773 |
| 3 | Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 711 |
| 4 | Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma Hit paper breakdown → | 2016 | 602 |
| 5 | 1996 | 549 | |
| 6 | Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma Hit paper breakdown → | 2015 | 536 |
| 7 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial Hit paper breakdown → | 2016 | 483 |
| 8 | Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma Hit paper breakdown → | 2019 | 470 |
| 9 | Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy Hit paper breakdown → | 1993 | 463 |
| 10 | Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Hit paper breakdown → | 2013 | 446 |
| 11 | Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study Hit paper breakdown → | 2020 | 403 |
| 12 | 2000 | 398 | |
| 13 | Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Hit paper breakdown → | 2015 | 354 |
| 14 | 2003 | 319 | |
| 15 | Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study Hit paper breakdown → | 2019 | 301 |
| 16 | 1995 | 292 | |
| 17 | 2017 | 291 | |
| 18 | 2010 | 281 | |
| 19 | 2010 | 278 | |
| 20 | 1999 | 260 |
About Peter Johnson
Peter Johnson is a scholar working on Pathology and Forensic Medicine, Immunology, Genetics, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 685 papers that have together received 32.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (223 papers), Chronic Lymphocytic Leukemia Research (80 papers), Monoclonal and Polyclonal Antibodies Research (77 papers), Reproductive System and Pregnancy (64 papers), Lung Cancer Treatments and Mutations (54 papers), CAR-T cell therapy research (40 papers), Pregnancy and preeclampsia studies (40 papers) and Immune Cell Function and Interaction (39 papers). The work is most often cited by research in Pathology and Forensic Medicine (12.0k citations), Genetics (5.7k citations), Immunology (7.5k citations), Oncology (8.7k citations) and Obstetrics and Gynecology (1.6k citations). Peter Johnson has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Martin J. Glennie, Judith Nicola Bulmer, John A. Radford, W. Pagé Faulk, Graham Packham, Mark Steven Cragg, Ruth R. French, ANDREW S. JACK, Keith W. Caldecott and Saïd Aoufouchi. Their work appears in journals such as Blood, Hematological Oncology, Journal of Clinical Oncology, Journal of Reproductive Immunology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.